499 related articles for article (PubMed ID: 28362144)
21. Vedolizumab: an α4β7 integrin inhibitor for inflammatory bowel diseases.
Smith MA; Mohammad RA
Ann Pharmacother; 2014 Dec; 48(12):1629-35. PubMed ID: 25186623
[TBL] [Abstract][Full Text] [Related]
22. Safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis.
Hagan M; Cross RK
Expert Opin Drug Saf; 2015; 14(9):1473-9. PubMed ID: 26138111
[TBL] [Abstract][Full Text] [Related]
23. Vedolizumab: An integrin-receptor antagonist for treatment of Crohn's disease and ulcerative colitis.
Hahn L; Beggs A; Wahaib K; Kodali L; Kirkwood V
Am J Health Syst Pharm; 2015 Aug; 72(15):1271-8. PubMed ID: 26195652
[TBL] [Abstract][Full Text] [Related]
24. Vedolizumab for the Treatment of Adults with Moderate-to-Severe Active Ulcerative Colitis: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Essat M; Tappenden P; Ren S; Bessey A; Archer R; Wong R; Lobo A; Hoque S
Pharmacoeconomics; 2016 Mar; 34(3):245-57. PubMed ID: 26477040
[TBL] [Abstract][Full Text] [Related]
25. Vedolizumab: A New Opponent in the Battle Against Crohn's Disease and Ulcerative Colitis.
Poulakos M; Machin JD; Pauly J; Grace Y
J Pharm Pract; 2016 Oct; 29(5):503-15. PubMed ID: 25952593
[TBL] [Abstract][Full Text] [Related]
26. Surrogate markers and clinical indices, alone or combined, as indicators for endoscopic remission in anti-TNF-treated luminal Crohn's disease.
af Björkesten CG; Nieminen U; Turunen U; Arkkila P; Sipponen T; Färkkilä M
Scand J Gastroenterol; 2012 May; 47(5):528-37. PubMed ID: 22356594
[TBL] [Abstract][Full Text] [Related]
27. Granulocytapheresis in steroid-dependent and steroid-resistant patients with inflammatory bowel disease: a prospective observational study.
Sacco R; Romano A; Mazzoni A; Bertini M; Federici G; Metrangolo S; Parisi G; Nencini C; Giampietro C; Bertoni M; Tumino E; Scatena F; Bresci G
J Crohns Colitis; 2013 Dec; 7(12):e692-7. PubMed ID: 23870727
[TBL] [Abstract][Full Text] [Related]
28. Natural history of elderly-onset inflammatory bowel disease: a population-based cohort study.
Charpentier C; Salleron J; Savoye G; Fumery M; Merle V; Laberenne JE; Vasseur F; Dupas JL; Cortot A; Dauchet L; Peyrin-Biroulet L; Lerebours E; Colombel JF; Gower-Rousseau C
Gut; 2014 Mar; 63(3):423-32. PubMed ID: 23408350
[TBL] [Abstract][Full Text] [Related]
29. Outcome after discontinuation of TNFα-blocking therapy in patients with inflammatory bowel disease in deep remission.
Molander P; Färkkilä M; Salminen K; Kemppainen H; Blomster T; Koskela R; Jussila A; Rautiainen H; Nissinen M; Haapamäki J; Arkkila P; Nieminen U; Kuisma J; Punkkinen J; Kolho KL; Mustonen H; Sipponen T
Inflamm Bowel Dis; 2014 Jun; 20(6):1021-8. PubMed ID: 24798636
[TBL] [Abstract][Full Text] [Related]
30. [Current position on Vedolizumab for ulcerative colitis and Crohn's disease].
Schreiber S; Dignass AU; Hartmann H; Kruis W; Rogler G; Siegmund B; Stallmach A; Witte C; Bokemeyer B
Z Gastroenterol; 2015 Jun; 53(6):591-602. PubMed ID: 26016456
[TBL] [Abstract][Full Text] [Related]
31. Vedolizumab: a review of its use in adult patients with moderately to severely active ulcerative colitis or Crohn's disease.
Garnock-Jones KP
BioDrugs; 2015 Feb; 29(1):57-67. PubMed ID: 25502899
[TBL] [Abstract][Full Text] [Related]
32. Calprotectin is a stronger predictive marker of relapse in ulcerative colitis than in Crohn's disease.
Costa F; Mumolo MG; Ceccarelli L; Bellini M; Romano MR; Sterpi C; Ricchiuti A; Marchi S; Bottai M
Gut; 2005 Mar; 54(3):364-8. PubMed ID: 15710984
[TBL] [Abstract][Full Text] [Related]
33. Does fecal calprotectin predict relapse in patients with Crohn's disease and ulcerative colitis?
García-Sánchez V; Iglesias-Flores E; González R; Gisbert JP; Gallardo-Valverde JM; González-Galilea A; Naranjo-Rodríguez A; de Dios-Vega JF; Muntané J; Gómez-Camacho F
J Crohns Colitis; 2010 Jun; 4(2):144-52. PubMed ID: 21122498
[TBL] [Abstract][Full Text] [Related]
34. Efficacy of adalimumab for the management of inflammatory bowel disease in the clinical setting.
Trinder MW; Lawrance IC
J Gastroenterol Hepatol; 2009 Jul; 24(7):1252-7. PubMed ID: 19220669
[TBL] [Abstract][Full Text] [Related]
35. The association of infliximab trough levels with disease activity in pediatric inflammatory bowel disease.
Hoekman DR; Brandse JF; de Meij TG; Hummel TZ; Löwenberg M; Benninga MA; D'Haens GR; Kindermann A
Scand J Gastroenterol; 2015; 50(9):1110-7. PubMed ID: 25865965
[TBL] [Abstract][Full Text] [Related]
36. Methotrexate in the treatment of inflammatory bowel disease: an 8-year retrospective study in a Canadian pediatric IBD center.
Willot S; Noble A; Deslandres C
Inflamm Bowel Dis; 2011 Dec; 17(12):2521-6. PubMed ID: 21337668
[TBL] [Abstract][Full Text] [Related]
37. Real-World Effectiveness of Vedolizumab vs Anti-TNF in Biologic-naïve Crohn's Disease Patients: A 2-year Propensity-score-adjusted Analysis from the VEDOIBD-Study.
Bokemeyer B; Plachta-Danielzik S; di Giuseppe R; Efken P; Mohl W; Hoffstadt M; Krause T; Schweitzer A; Schnoy E; Atreya R; Teich N; Trentmann L; Ehehalt R; Hartmann P; Schreiber S
Inflamm Bowel Dis; 2024 May; 30(5):746-756. PubMed ID: 37523666
[TBL] [Abstract][Full Text] [Related]
38. Crohn's disease and ulcerative colitis. Occurrence, course and prognosis during the first year of disease in a European population-based inception cohort.
Burisch J
Dan Med J; 2014 Jan; 61(1):B4778. PubMed ID: 24393595
[TBL] [Abstract][Full Text] [Related]
39. Proactive therapeutic drug monitoring and vedolizumab dose optimization in children with inflammatory bowel disease.
Rowland P; McNicol M; Kiel A; Maltz RM; Donegan A; Dotson JL; Michel HK; Boyle B
J Pediatr Gastroenterol Nutr; 2024 Apr; 78(4):853-861. PubMed ID: 38270212
[TBL] [Abstract][Full Text] [Related]
40. Clinical status, psychosocial impairments, medical treatment and health care costs for patients with inflammatory bowel disease (IBD) in Germany: an online IBD registry.
Bokemeyer B; Hardt J; Hüppe D; Prenzler A; Conrad S; Düffelmeyer M; Hartmann P; Hoffstadt M; Klugmann T; Schmidt C; Weismüller J; Mittendorf T; Raspe H
J Crohns Colitis; 2013 Jun; 7(5):355-68. PubMed ID: 22503168
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]